- The disease
- Onychomycosis is a fungal infection of the nail, most commonly affecting the toenails. It is caused mainly by dermatophyte fungi and leads to nail thickening, discolouration, and brittleness. The condition is common in adults and can be difficult to treat because topical agents must penetrate the nail plate to reach the infection site. Oral antifungal treatments are effective but carry systemic side-effect risks, which has driven interest in topical alternatives.
- What the asset is trying to do
- Efinaconazole 10% is a topical azole antifungal agent that works by inhibiting fungal cell membrane synthesis, specifically by blocking the enzyme lanosterol 14-alpha-demethylase, which fungi require to produce ergosterol. The reference branded product is Jublia (efinaconazole 10% topical solution), approved by the US FDA. Acrux is developing a generic version of Jublia under the US Abbreviated New Drug Application (ANDA) regulatory pathway, which requires demonstration of bioequivalence to the reference listed drug rather than independent efficacy trials.
- What the trial is measuring, and why it matters
- Because this asset follows the ANDA generic pathway, the regulatory submission centres on demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug (Jublia), rather than running new Phase 2 or Phase 3 efficacy trials. The clinical trials listed in the asset record relate to earlier Acrux testosterone products and are not associated with the efinaconazole programme. Key regulatory data requirements for a topical antifungal ANDA include in vitro and in vivo bioequivalence studies per FDA guidance.
- Efficacy benchmarks in this setting
- The reference listed drug, Jublia (efinaconazole 10% topical solution), was approved by the FDA in June 2014 for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes (per FDA approval announcement, June 2014). In the pivotal trials supporting Jublia's approval, complete cure rates (clear nail plus mycological cure) at 52 weeks were reported at approximately 17.8% and 15.2% in two studies (per Jublia US prescribing information, Bausch Health). Early-stage or bioequivalence figures for generic products are not statistically comparable to the pivotal branded-product trial data.